CRDA

Croda International has spent the last century quietly becoming one of the most respected specialty chemistry companies in Europe. It does not make bulk chemicals. It makes ingredients: the emulsifiers inside cosmetics, the adjuvants that help crop protection agents adhere to leaves, the lipid nanoparticles that carried the active mRNA payload in the Pfizer-BioNTech COVID-19 vaccine. For decades, this business model delivered a combination of high gross margins, consistent compounding, and defensive characteristics that allowed Croda to trade at a premium to the broader European chemicals sector. The stock was a staple of quality-oriented UK equity portfolios. Then the model cracked.

Between 2022 and 2025, revenue fell from GBP 2.09 billion to GBP 1.70 billion. Net income collapsed from GBP 649 million to GBP 62 million. Return on invested capital, which historically approached or exceeded 15%, now sits at 5.6%, below any reasonable estimate of the company's cost of capital. The dividend, once a symbol of quality compounding, is now being paid out at more than 250% of earnings. The share price, which peaked above 10,000 pence in early 2022, trades at 2,934 pence as of April 2026, a decline of more than 70% from the peak.

The central analytical observation that cannot be found in any standard data provider is this: Croda's apparent moat in specialty ingredients was, for a critical window of years, artificially amplified by two exceptional demand shocks, the pandemic-era lipid nanoparticle boom in Life Sciences and the post-pandemic restocking cycle in Consumer Care. Strip both out, and what remains is a good but cyclically exposed formulation house whose structural pricing power over customers is narrower than the pre-2023 narrative suggested. The question this analysis addresses is whether Croda remains a Status-Quo-Player in specialty ingredients, or whether the destocking cycle has revealed a company that must now fight, rather than defend, its position. The evidence suggests the latter.